Tobacco Dependence Clinical Trial
Official title:
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
The purpose of this study was to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix™, is an U.S. Food and Drug Administration (FDA) approved medication that has been shown to help people quit smoking. This study was trying to evaluate whether varenicline would change the response to smoking and the desire for cigarettes when compared to an inactive placebo control. This was not a quit smoking treatment study, and participants were not asked or required to stop smoking while in this study.
We proposed the following primary hypotheses:
1. Tonic (i.e., non-cue-provoked) craving levels would be lower in participants receiving
varenicline versus placebo.
2. Cue-provoked cravings (self-report and physiological responding) would be lower in
participants receiving varenicline versus placebo. (Secondary indices of craving
include heart rate and skin conductance.)
3. The two primary indices of nicotine reward/reinforcement (mCEQ and choice index) would
be lower in participants receiving varenicline versus placebo. (Secondary indices of
nicotine reinforcement include smoking topography variables.)
A final sample of 100 non-treatment seeking daily smokers were recruited from the Tampa-St.
Petersburg-Clearwater Metropolitan Area via paid advertisements in, and press releases to,
local newspapers, as well as targeted outdoor advertising via flyers (e.g., on public
transportation).
Following the screening session, participants were randomly assigned to receive either
varenicline or placebo medication.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01928719 -
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
|
N/A | |
| Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
| Not yet recruiting |
NCT03249428 -
E-Cigarette Inner City RCT
|
N/A | |
| Recruiting |
NCT02564289 -
Cardiovascular Effects of Chronic Snus Use
|
N/A | |
| Completed |
NCT01928758 -
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
|
N/A | |
| Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
| Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
| Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
| Recruiting |
NCT00977249 -
Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00968513 -
Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
|
Phase 3 | |
| Completed |
NCT01113424 -
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
|
N/A | |
| Completed |
NCT00722124 -
S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
|
Phase 2/Phase 3 | |
| Completed |
NCT01238627 -
Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg
|
N/A | |
| Completed |
NCT01228617 -
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
|
N/A | |
| Completed |
NCT00296647 -
Smoking Cessation Intervention: Effectiveness in Primary Care
|
Phase 4 | |
| Completed |
NCT00394420 -
Emergency Department Telephone Quitline
|
N/A | |
| Recruiting |
NCT05487807 -
Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia
|
Phase 1 | |
| Completed |
NCT03553992 -
An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers
|
N/A | |
| Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
| Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A |